Baseline Serum Autoantibody Signatures Predict Recurrence and Toxicity in Melanoma Patients Receiving Adjuvant Immune Checkpoint Blockade.

Paul JohannetWenke LiuDavid FenyoMegan Wind-RotoloMichelle KrogsgaardJanice M MehnertJeffrey S WeberJudy ZhongIman Osman

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

Baseline serum autoAb signatures predicted recurrence and severe toxicity in patients treated with adjuvant immunotherapy. Prospective testing of the signatures that include datasets with longer follow-up and rare but more severe toxicities will help determine their generalizability and potential clinical utility. See related commentary by Hassel and Luke, p. 3914.

Keyphrases

genome wide
early stage
early onset
oxidative stress
free survival
drug induced
gene expression
climate change